# Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

> **NCT05789043** · PHASE3 · RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 140 (estimated)

## Conditions studied

- Acral Melanoma

## Interventions

- **DRUG:** camrelizumab+apatinib+TMZ
- **DRUG:** camrelizumab+apatinib
- **DRUG:** camrelizumab

## Key facts

- **NCT ID:** NCT05789043
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-21
- **Primary completion:** 2026-08-15
- **Final completion:** 2027-02-15
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2023-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05789043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05789043, "Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05789043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*